Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in <i>CTNNB1</i> -mutated endometrial cancer
Bradley R. Corr(University of Colorado System), Benjamin G. Bitler(University of Colorado Denver)
Cited by 6
Related Papers
CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer
|Oncogenesis|2018|86
Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma
|Molecular Cancer Therapeutics|2022|21
Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression
|Cancer Research Communications|2024|21
Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
|Molecular Cancer Therapeutics|2022|17
Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation
|Molecular Cancer Therapeutics|2024|11